PMV Pharmaceuticals, Inc. PMVP
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is an oncology drug developer. Its lead program, rezatapopt (PC14586), is in Phase 2 for TP53 Y220C-mutant solid tumors; platinum-resistant/refractory ovarian cancer. Its next catalyst on record is rezatapopt: PMV Pharmaceuticals plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in first quarter of 2027. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: rezatapopt — PMV Pharmaceuticals plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in first quarter of 2027. (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rezatapopt | TP53 Y220C solid tumors (tumor-agnostic), ovarian cancer lead | small molecule | Phase 2 |
Recent results and decisions
- Oct 5, 2026completed enrollment PMV Pharma completed enrollment in the Phase 2 monotherapy portion of the PYNNACLE Phase 2 pivotal clinical trial for rezatapopt.
Dr. Eckler joins the Board following completion of enrollment in the Phase 2 monotherapy portion of the ongoing PYNNACLE Phase 2 pivotal clinical trial
Filing - Oct 1, 2026completed enrollment PMV Pharma completed enrollment in the Phase 2 monotherapy portion of the PYNNACLE pivotal trial.
Dr. Eckler joins the Board following completion of enrollment in the Phase 2 monotherapy portion of the ongoing PYNNACLE Phase 2 pivotal clinical trial
Filing - Oct 1, 2026n/a PMV Pharmaceuticals appointed Matt Eckler, Ph.D., to its Board of Directors.
On October 1, 2026, Dr. Matthew Eckler was appointed to the board of directors of PMV Pharmaceuticals, Inc.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.